Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Hi Daisan I do have a reasonably limited holding as a percentage of portfolio , I have held for a long time through the deep dip so still underwater for a while yet I actually know an Azerbaijani here in Australia , when I was chatting to him about the Ukraine , he said yes we are all watching that one closely , we also chatted about the CIS in general - I spent a couple of months traveling independently through the whole region in 98 , I said , "You know I got the impression that the soviet days were nowhere near as bad as we were told in the UK in the cold war years" His response "yes In fact quite a lot of people are actually talk fondly about the old days , for the everyday person life was better in a lot of ways as part of the USSR" Obviously this is the thoughts of one person , others will have different views , but it does make me wonder how much resistance there would be to returning to the old days - what that return would mean for foreign investment is also up for debate - Putin is definitely a bit more capitalist friendly than the old guard As I mentioned previously the whole Oxus gold and gulnara karimova saga leaves me a little twitchy about these situations
Hi Rising Star , no it does not explain , it does though as I mentioned mirror my question of Why? This one is better - although written by an author who clearly declares himself as being lon on AZN http://seekingalpha.com/article/4025891-astrazeneca-buy-hits-new-52-week-lows?ifp=0
http://www.coface.com/Economic-Studies-and-Country-Risks/Azerbaijan
Today's market overview News & Tips: AstraZeneca, Mitchells & Butlers, Compass & more Shares in London have added more than 1 per cent in early trading as investors follow the lead from over the pond. For The Trader Nicole Elliott's latest views on the markets, click here. IC TIP UPDATES: This was it 22nd November Investors chronicle update AstraZeneca (AZN) has got its head and neck cancer drug trials back on track after surprising side effects forced the group to halt recruitment last month. The shares have dive bombed since - unsurprising really since management had put so many hopes on the success of the drug in question. But the drug is just one constituent in Astra’s very impressive oncology portfolio and we think recent share price weaknesses merely highlight the current buying opportunity.
Nice to see others share my confusion! http://www.investorschronicle.co.uk/2016/11/22/shares/news-and-analysis/news-tips-astrazeneca-mitchells-butlers-compass-more-YONEbBmanH5ArLdGOSo7MM/article.html?utm_campaign=ICDailyEmail_2013&utm_source=emailCampaign&utm_medium=email&utm_content=
Have I missed some bad news ? generally good broker forecasts clinical trials re starting for head and neck But still falling sp ? Maybe if someone came along with a bit over 50 quid a share they could buy the company and save me a lot of head scratching?! :-)
Well like everybody else I wish I'd known this was happening a few hours earlier , I could of skipped out and in again ,but in the bigger picture, I think that they have found support at close to 320 demonstrates the robustness of this share/company , I guess the fact I bought in at 212 on june 24 when everybody was throwing themselves off a cliff makes it easier to be relaxed about it :-)
Hi Daisan I hope you are right , the numbers are definitely good , I Hold a bit of gold in a physical backer etf , more as a "if it all goes of the tracks rapidly" kind of balancer rather than really trading in or out ,so I am reading all the conflicting gold predictions, I may well be a bit over sensitive to Geopolitical risk as I was also invested in Oxus Gold ,that did not end well, despite my slight nervousness I remain invested in AAZ - I'm right back up to only 30% down now so I think I'll hold on for a pay cheque
Hi Daisan , I hope I am wrong about the geopolitical risk and Trump as President , I guess the best indicator would be to ask residents of Azerbaijan whether they now feel more or less comfortable about Russia looking at old USSR maps...
From Seeking Alpha AstraZeneca has agreed to sell its small-molecule antibiotics operations to Pfizer (NYSE:PFE) in a transaction that could eventually be worth $1.575B. The deal will allow AstraZeneca (AZN -0.15% premarket) to focus on three main therapy areas and realize value "from the strong portfolio of established and late-stage small molecule antibiotics." Pfizer will pay $550M upfront plus $175M in January 2019, and as much as $850M in milestones and sales-related payments.
From IC Pharma giant AstraZeneca (AZN) has agreed to sell its late-stage antibiotics business to acquisition hungry Pfizer. The US group will pay Astra up to $1.5bn for its portfolio which consists of three already approved antibiotics and two currently undergoing clinical trials. According to management at Astra this will allow the group to focus more on its three main therapy areas, while allowing Pfizer - a world leader in infectious diseases - to bring its antibiotics to market effectively. The deal is not expected to impact current year forecasts and we still rate Astra a buy.